Cancer Therapy News and Research

RSS

Epitomics launches EP Clone Rabbit Monoclonal Antibodies

Epitomics, Inc., the rabbit monoclonal antibody company, announces today the launch of EP Clone™ Rabbit Monoclonal Antibodies and their detection systems for pathology applications. These diagnostic immunohistochemistry (IHC) products are manufactured by the In Vitro Diagnostic (IVD) Division of the Company. This new line of products are developed in compliance with regulation for IHC antibodies and detection systems in the United States, these products are manufactured under FDA's Quality System Regulation (21 CFR, Part 820).

9 Aug 2010

ESMO Congress provides forum for presentation of new research on treatment of cancer

Cancer is a leading cause of mortality worldwide, accounting for more than one in ten deaths. By 2030, the global burden is expected to exceed 12 million.

9 Aug 2010

Magnetic relaxometry with heat treatment improves treatment of tumours by nanoparticles

Those who have to fight a powerful enemy must look for allies. This is why physicists from different scientific fields have decided to cooperate with biomedical physicians in order to place the fight against cancer through heat treatment by means of magnetic nanoparticles on a solid, scientific basis. It is the objective of the cooperation to improve the success of the therapy.

9 Aug 2010

BCF publishes two new patient publications

The Bone and Cancer Foundation is announcing the publishing of two new patient publications on Pain Management and Physical Therapy and other Rehabilitation Therapies. Other publication topics include: Breast Cancer, Prostate Cancer, Lung Cancer, Osteonecrosis of the Jaw, Vitamin D, Surgery, Myeloma and Osteosarcoma.

7 Aug 2010

NAEDI aims to correct survival gap in cancer diagnosis

Cancer Research UK today reveals that as many as 11,000 deaths from cancer could be prevented annually if Great Britain raised its survival figures to match those of the best performing countries in Europe.Cancer Research UK and national cancer director, Professor Mike Richards, believe that the most important reasons for the survival gap include poor awareness of the symptoms of cancer, late presentation to a GP and, late onward referral to hospital.

6 Aug 2010

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

Sanofi-aventis U.S. announced today that the U.S. Food and Drug Administration (FDA) has approved a new one-vial formulation of its chemotherapeutic agent Taxotere® (docetaxel) Injection Concentrate. The 1-vial Taxotere is anticipated to become available to cancer treatment clinics and hospitals nationwide in the fall in both 80 mg and 20 mg dosages.

5 Aug 2010

New study reinforces need for national catastrophic drug plan in Canada for cancer patients

In a newly released report comparing international usage of prescription drugs, Canada ranks thirteenth among 14 countries for cancer drugs launched within the last five years. The study, conducted for the UK Secretary of State for Health, compared 14 countries for their usage of 14 categories of prescription drugs to determine whether the UK is adequately providing for the health needs of its citizens.

5 Aug 2010

CTI second-quarter total net operating expenses decrease to $20.0 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the second quarter ended June 30, 2010.

5 Aug 2010

Siteman Cancer Center to test radiotherapy system from ViewRay

Researchers at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri, a national leader in the early adoption and use of advanced treatments for cancer patients, will soon become the first in the world to test an innovative radiotherapy system from ViewRay, Inc. The ViewRay system is designed to improve the accuracy of cancer treatments through a combination of medical imaging and radiotherapy delivery.

4 Aug 2010

Kohl's, American Cancer Society announce new program to fight against breast cancer

As part of Kohl's Department Stores' commitment to fight breast cancer in Wisconsin with nearly $5 million to the American Cancer Society, Kohl's and the American Cancer Society announce new programs and resources available for Wisconsin women to help in their fight against breast cancer. New resources provide services for women fighting breast cancer and for those looking to learn more about preventative breast health.

4 Aug 2010

Curis reports net loss of $2.1 million for second-quarter 2010

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the second quarter ended June 30, 2010.

3 Aug 2010

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

Researchers at Columbia University have published the dramatic effects of a natural 33-ingredient compound against prostate cancer cell lines. The impressive results are found in the most recent publication of Integrative Cancer Therapies.

3 Aug 2010

First patient treated in Phase Ib expansion study of CUDC-101

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that the first patient has been treated in a Phase Ib expansion study for CUDC-101 in patients with advanced head and neck, gastric, breast and liver cancers.

3 Aug 2010

OHSU acquires BSD-500 Hyperthermia System

BSD Medical Corporation is pleased to announce that Oregon Health & Science University has acquired a BSD-500 Hyperthermia System. OHSU is a leading university that provides world-class treatment for the most complex health care needs. OHSU has been ranked in U.S. News & World Report's annual rankings as one of America's Best Hospitals for 15 consecutive years and has been recognized in the medical specialties of cancer and endocrinology.

2 Aug 2010

MBHS targets emerging healthcare markets of Russia, CIS

mBeach Software Inc. today announced a strategy of targeting new international market opportunities. In particular, the company has identified the emerging markets of Russia and Commonwealth of Independent States.

31 Jul 2010

Pathwork Diagnostics enters into research collaboration with Novartis

Pathwork Diagnostics Inc., a molecular diagnostics company focused on oncology, today announced that it has entered into a research collaboration with Novartis. The parties intend to discover clinically meaningful biomarker signatures that can serve as the basis for diagnostics across a range of cancer types. Under the terms of the agreement, both parties have rights to develop and commercialize the diagnostic products. Financial terms were not disclosed.

31 Jul 2010

Galangin mediates apoptosis of hepatocellular carcinoma cells through mitochondrial pathway: Study

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, particularly in China. However, HCC remains one of the more difficult cancers to treat. It is important to screen for new anti-cancer drugs. A number of dietary compounds possess anti-cancer properties. These dietary compounds may modify the activity of specific targets that control cell proliferation and apoptosis. Galangin could inhibit the methoxyresorufin O-demethylase activity of CYP1A2, CYP1A1 and P-form phenolsulfotransferase.

31 Jul 2010

Scientists identify new targets to develop treatment for HD

Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases, provide new targets for drug therapies for the disease - targets that have already been shown to respond to cancer drugs currently in clinical development.

29 Jul 2010

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.

28 Jul 2010

Navigating Cancer creates new application to help patients manage, update medical history

Navigating Cancer is putting the power of cancer treatment advocacy and management into the hands of cancer patients. The free website, which empowers cancer patients to take an active role in their care and partner more closely with their physicians during treatment, has created a unique medical history form that enables patients to manage and update their medical history on demand.

27 Jul 2010

Cancer Therapy News and Research

Epitomics launches EP Clone Rabbit Monoclonal Antibodies

ESMO Congress provides forum for presentation of new research on treatment of cancer

Magnetic relaxometry with heat treatment improves treatment of tumours by nanoparticles

BCF publishes two new patient publications

NAEDI aims to correct survival gap in cancer diagnosis

Sanofi-aventis receives FDA approval for new Taxotere Injection Concentrate formulation

New study reinforces need for national catastrophic drug plan in Canada for cancer patients

CTI second-quarter total net operating expenses decrease to $20.0 million

Siteman Cancer Center to test radiotherapy system from ViewRay

Kohl's, American Cancer Society announce new program to fight against breast cancer

Curis reports net loss of $2.1 million for second-quarter 2010

Effects of natural compound against prostate cancer published in Integrative Cancer Therapies

First patient treated in Phase Ib expansion study of CUDC-101

OHSU acquires BSD-500 Hyperthermia System

MBHS targets emerging healthcare markets of Russia, CIS

Pathwork Diagnostics enters into research collaboration with Novartis

Galangin mediates apoptosis of hepatocellular carcinoma cells through mitochondrial pathway: Study

Scientists identify new targets to develop treatment for HD

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Navigating Cancer creates new application to help patients manage, update medical history

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News